Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review
| Autor: | W C Kisseberth, Janean Fidel, Evan T. Keller, B. Kitchell, J E Obradovich, R C Rosenthal, Ilene D. Kurzman, Stuart C. Helfand, David M. Vail, E G MacEwen, Carlos O. Rodriguez, C L London, Leslie E. Fox, Bruce R. Madewell, S. Susaneck, M. Rosenberg |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
medicine.medical_specialty
Pathology Lung Neoplasms Cyclophosphamide medicine.medical_treatment Hemangiosarcoma Pharmaceutical Science Antineoplastic Agents Bone Neoplasms Gastroenterology Metastasis Dogs Internal medicine medicine Animals Doxorubicin Dog Diseases Prospective Studies Cisplatin Chemotherapy Osteosarcoma business.industry Phosphatidylethanolamines Splenic Neoplasms Combination chemotherapy medicine.disease business Acetylmuramyl-Alanyl-Isoglutamine medicine.drug |
| Zdroj: | Journal of drug targeting. 2(5) |
| ISSN: | 1061-186X |
| Popis: | Targeted delivery of macrophage activating agents is an attractive approach to treat micrometastatic disease. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) is a potent activator of monocytes/macrophages in humans, mice, and dogs. We have conducted clinical trials in dogs with malignant and highly metastatic spontaneous tumors. Presented are results of our trials evaluating L-MTP-PE in combination with surgery and chemotherapy in dogs with spontaneous osteosarcoma and hemangiosarcoma, particularly relevant malignancies having having many similarities to human cancer. Osteosarcoma dogs received chemotherapy following surgery (cisplatin q 28 days x 4). At completion of chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p0.021). Dogs with splenic hemangiosarcoma received combination chemotherapy following surgery (doxorubicin and cyclophosphamide q 21 days x 4). At the first chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p0.03). These studies show that L-MTP-PE is an effective agent for treatment of metastasis and can be safely administered in combination with chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|